FIGS (FIGS) Stock Looks Overvalued On Cash Flow And Earnings
FIGS stock has more than doubled over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples still flag the shares as expensive relative to the underlying cash flow profile. That gap between a strong three year return and valuation checks that lean rich is what investors now have to weigh.
- The share price has delivered a 144.7% gain over three years, which puts recent enthusiasm well ahead of many peers and raises the bar for future execution.
- The long term story can be supported by FIGS expanding its direct to consumer reach and product range. However, any pressure on margins or slower cash generation may quickly matter more now that expectations are higher.
- The broader valuation work, including a DCF intrinsic value estimate and market multiples, both screen FIGS as overvalued, and the low value score of 1 suggests the stock does not screen as a clear bargain on these checks.
The issue now is whether the current FIGS share price already reflects the business that investors hope to see in a few years, or if there is still room for upside based on fundamentals alone.
Balance that strong FIGS run by scanning a curated list of other potential opportunities screened for value and quality through 49 high quality undervalued stocks.
Does FIGS Look Pricey on Cash Flow?
The Discounted Cash Flow (DCF) model here values FIGS based on the cash it is expected to generate for shareholders over time. FIGS has reported latest twelve month free cash flow of about $90.6 million, and the model uses a set of relatively flat projections that treat future free cash flows as broadly stable rather than rapidly rising or falling.
On those cash flow assumptions, the DCF points to an estimated intrinsic value of about $9.45 per share. With the current share price sitting meaningfully above that figure, the model output implies the stock screens as overvalued by about 44.7% on this cash flow view.
On these cash flow projections, FIGS stock currently screens as overvalued relative to its DCF based intrinsic value estimate.
Our Discounted Cash Flow (DCF) analysis suggests FIGS may be overvalued by 44.7%. Discover 49 high quality undervalued stocks or create your own screener to find better value opportunities.
Is FIGS Getting Expensive on Earnings?
P/E works reasonably well for FIGS because the business is generating positive earnings that can be compared directly with the share price. On this check, the stock trades on a P/E of about 36.7x, which is more than double the luxury industry average of roughly 15.5x and also well above the peer group average of 17.5x.
The fair P/E ratio implied by the model is about 15.2x, so the current multiple sits a long way above what would typically be expected once factors like growth profile, profitability and risk are blended in. That gap means buyers today are paying a rich earnings premium for FIGS relative to both its sector and the more tailored fair ratio benchmark.
On this P/E yardstick, FIGS stock appears expensive compared with both industry norms and the model’s fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The FIGS Narrative: What Would Justify Today's Price?
FIGS' Simply Wall St Narratives pick up where the valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today’s price on the Community page. Each scenario links its number to a clear view on how FIGS' future expansion, profitability and risk profile might shift, giving you something concrete to revisit as fresh results emerge.
One of the top community narratives on FIGS: roughly fairly valued
"FIGS concentrates on a specific niche within the healthcare industry, medical professionals, and tailors its products to precisely match their requirements..."
Read one of the top narratives on FIGS
Do you think there's more to the story for FIGS? Head over to our Community to see what others are saying!
The Bottom Line
FIGS screens as overvalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the current P/E multiple, so the valuation debate now turns on whether the business can grow into that richer pricing. The key question is whether FIGS can sustain cash generation and protect margins strongly enough to close the gap to its intrinsic value estimate without relying on further multiple expansion. For investors watching from here, the crux is simple: either earnings and free cash flow ultimately justify paying up, or the premium rating leaves limited room for disappointment.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com